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tumor progression in the bone, we have previously identified a group of enzymes known as matrix metalloproteinases (MMPs) as being highly overexpressed at the tumor bone interface in comparison to the tumor area alone. In a bid to understand the importance of these MMPs, namely MMP-2, -3, -9 and -13, in prostate tumor progression in the bone, we aim to generate MMP null animals and compare those animals to their wild type counterparts. While the MMPs are important in the turnover of the extracellular matrix, it has become apparent that the MMPs are also capable of regulating cell:cell communication by processing various cytokines and growth factors to active soluble forms (5) . These soluble factors often influence biological processes including survival, proliferation, angiogenesis and osteoclast activation. Therefore, understanding which MMPs are important in contributing to prostate tumor progression in the bone and identifying the mechanisms that govern the vicious cycle can provide valuable targets for therapeutic development. b) Using our pre-clinical animal models, we will test the contribution of stromal MMP-9 to tumor induced osteoblastic and osteolytic change in readily available immunocompromized RAG-2 -/-MMP-9 deficient mice (Months 1-12).
c) Test the contribution of stromal MMP-2, MMP-3 and MMP-13 to tumor induced osteoblastic and osteolytic change using our pre-clinical model (Months 11-30). The amount of pathological bone (dashed line) was assessed in sections from WT (n=24) and MMP-9 deficient (n=37) animals at week 3. The number of osteoblasts generating pathological bone was also measured. B:
The numbers of TRAP positive multinucleated osteoclasts (green) at the tumor bone interface (dashed line) in multiple sections revealed no difference in numbers between the WT and MMP-9 deficient groups. DAPI (blue) was used as a nuclear stain. No differences in the bone destruction indices were observed. Arrows indicate areas of osteolysis. In the initial 12 months of the project, we focused on assessing the impact of host derived MMP-9 in tumor induced osteolytic and osteoblastic changes. We observed that the cell responsible for bone destruction, the osteoclast, was the major cellular source of MMP-9 in the prostate tumor-bone microenvironment in our animal model. The clinical relevance of this observation was also tested. In collaboration with Dr. Bob Vessella, University of Washington (6, 7), we assessed the expression of -/-osteoclast culture conditioned media (CM) at day 7. The average distance of sprout migration was calculated from photomicrographs on a daily basis.
Scale bar represents 1mm. n.s. denotes non-significant (p>0.05) p values. * denotes p<0.05, ** denotes that p<0.01, *** denotes that p<0.001. MMP-9 in 10 human samples of prostate to bone metastasis and observed that again, osteoclasts were a major cellular source of MMP-9 in the human prostate tumor-bone microenvironment. To test whether host MMP-9 contributed to prostate tumor induced osteolysis or osteogenesis, we utilized immunocompromized animals that were either wild type or null for host MMP-9.
In repeated studies, with at least 10 animals per group, we determined that MMP-9 does not have any effect on tumor progression in the bone using both whole animal imaging modalities such as microCT and microSPECT and traditional histomorphometry approaches. While there was a trend towards a decrease in osteolysis in the MMP-9 deficient animals, this decrease did not prove to be statistically significant ( Figure 1 ). While these data suggest that MMP-9 does not contribute to tumor progression in the bone, it should be stated that the role of MMP-9 in 1) the metastasis of prostate cancer to the bone or 2) in the initial survival/establishment of the prostate tumor cells in the bone microenvironment can not be ruled out since these steps are not recapitulated in our animal model. Previous studies have shown that MMP-9 is important in mediating angiogenesis in the tumor microenvironment (8) and using the endothelial antigen CD-31 as a marker for angiogenesis, we found decreased angiogenesis in the MMP-9 null group. In follow-up experiments we identified that while MMP-9 did not impact the ability of myeloid cells to become mature multi-nucleated osteoclasts, there was a significant decrease in the ability of the MMP-9 null osteoclasts to mediate the bioavailability of the potent angiogenic factor vascular endothelial growth factor A (VEGF-A 164 ) ( Figure 2 ). This observation explains, in part, the reduced vascularity of the tumors in the MMP-9 null animals. These results therefore demonstrate that while host, specifically osteoclast derived MMP-9, does not contribute to tumor induced osteolysis and osteogenesis, it does contribute to angiogenesis in the tumor-bone microenvironment. Furthermore, our results resonate with emerging studies from other groups that establish the osteoclast as an angiogenic cell (9, 10).
These data have recently been reported in the journal Molecular Cancer Research (11) .
Host MMP-13 has a protective role in the prostate tumor-bone microenvironment
Murine MMP-13 is considered to be the ortholog of human MMP-1, and MMP-13 deficient animals have been reported as having a delay in endochondral ossification during skeletal development with thickened trabecular bone persisting in the animals (12, 13) . In collaboration with Dr. Stephen Krane, we generated immunocompromized MMP-13 deficient mice.
Histological analysis of the calvaria from these animals at 6 weeks of age and their age matched wild type counterparts were similar with respect to the amount of bone and number of osteoclasts (data not shown). Surprisingly, preliminary studies using our animal model suggested that host MMP-13 plays a protective role in preventing tumor induced osteolytic and osteoblastic changes (Figure 2 ). At three weeks post implantation, immunocompromized wild type and MMP-13 deficient animals were sacrificed. Histological analysis revealed that in comparison to wild type controls, MMP-13 deficient sections had higher numbers of osteoblasts and osteoclasts which was consistent with increase bone formation and destruction respectively. These data are unexpected since MMP-13 has been described as the rate limiting collagenase for murine skeletal development. These data suggested that in the pathological context of the tumor bone microenvironment, host MMP-13 inhibits the vicious cycle and plays a protective role in the tumor-bone microenvironment. The concept of MMPs as playing a protective role during tumor progression has been reported for MMP-3 and MMP-8 during skin carcinogenesis and progression in mice but to our knowledge MMP-13 has not been described as being protective in a pathological context (14, 15) . These studies have been repeated and we are currently exploring the mechanisms through which MMP-13 protects against prostate tumor progression in the bone.
Our collected data illustrated that MMP-7, -9 and -13 are highly expressed in the prostate tumor-bone microenvironment but on an individual basis, they clearly play very different roles with respect to tumor induced osteoblastic and osteolytic changes. In the final year of the proposal, we have also observed that host MMP-2 significantly impacts the progression of tumors in the bone microenvironment while host MMP-3 appears to play a limited role upon gross observations. Our currently research is focused on identifying how MMP-2 and MMP-13 can contribute to/or protect against prostate tumor progression in the bone microenvironment using our animal model. We anticipate that the results of these studies will be published within the next 12 months.
Conclusions from Aim 1. Initially we set out to test whether individual host MMPs contributed to prostate tumor progression in bone using a unique animal model. Our results and preliminary findings
show that in some cases, individual MMPs can contribute (MMP-7 and MMP-2) while others can be protective (MMP-13) or play more subtle roles (MMP-9). These findings support the conclusions drawn from human clinical trials with MMP inhibitors that stated in order to avoid the deleterious side effects of broad spectrum MMP inhibitors, the roles for individual MMPs needed to be elucidated so that more selective therapeutics could be generated. 
MMP-2 is a key regulator of TGFβ bioavailability
In our initial studies, we examined the presence of active TGFβ using ELISA techniques. While we observed that there is more active TGFβ at the tumor bone interface in comparison to the tumor area alone, we found no difference in the levels of active TGFβ between wild type, MMP-7 and MMP-9 null animals ( Figure 4 ). Given the labile nature of TGFβ we have taken multiple approaches into identifying the activity status of the cytokine in wild type and MMP null animals. Using procedures described by Barcellos-Hoff et al. (16) , we generated frozen sections of non-decalcified bone using the Cryo-Jane Tape transfer system. The approach allowed us to visualize latent and active TGFβ and the effectors of TGFβ such as phospho SMAD2 in the tumor-bone microenvironment using microscopy ( Figure 4) .
In parallel studies, we localized the major cellular sources of the MMPs under investigation in human and murine tumor-bone microenvironments. Surprisingly, we identified that osteoblasts and Immunoblot analysis also demonstrates PTHrP processing using an antibody directed to the C-terminus (Santa Cruz; sc-20728). D: N-terminal amino acid sequencing revealed that MMP-3 generated PTHrP . F. MALDITOF-MS showed that MMP-3 was capable of further processing of PTHrP . Similar analyses revealed no degradation of full length PTHrP in the absence of MMPs. E-F: MC3T3-E1 (10 5 cells per 6 well in triplicate) were incubated with 50nM PTHrP 1-36 or equimolar concentrations of PTHrP fragments corresponding to MMP-3 products. No difference in mineralization was determined by day 21 using alizarin red and spectrophotometry (E). However, treatment with PTHrP 1-16 significantly stimulated MC3T3 cell growth as assessed by MTT assay (F). molecular mechanism underlying this phenomenon (Figure 4) . We are currently repeating these experiments using our animal model system but are also using other models in order to test the role of osteoblast derived MMP-2 in tumor progression in the bone microenvironment. We anticipate that the findings of these studies will be published by the end of 2010.
PTHrP is a novel MMP substrate
In sequence similarities to endothelin-1 (ET-1). ET-1 has been identified as a major factor involved in promoting osteoblastic responses via the ET A receptor (20) . PTHrP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] has been shown to bind to ET A in cardiomyocytes but apparently has no impact on ET A signaling when overexpressed in CHO cells (21, 22) . However, the precise role of PTHrP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] in osteoblast function is unclear. Other MMP-3 generated fragments such as PTHrP [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] can mediate protein kinase C signaling via the PTHR-1 receptor (23) but again, the precise role of this fragment in addition to PTHrP [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] in osteoblast function remain unclear. Our initial experiments identified that the MMP generated fragments can impact the behavior of the osteoblasts with respect to growth but it does not appear that the fragments impact osteoblast differentiation and invasion. We are currently further assessing the in vitro and in vivo relevance of the MMP generated PTHrP products and they will be the focus of future studies.
MMPs generate an active soluble form of RANKL.
We have previously demonstrated that membrane bound receptor activator of nuclear κB ligand (RANKL) which is essential for osteoclast maturation and activation is sensitive to shedding from the cell surface by MMP-3 and MMP- 7 (24) and have found that the mechanism is not only relevant in the prostate tumor-bone microenvironment but also in the breast (25) . Experiments in this study have resulted in the generation of non-cleavable of RANKL and future studies are focused on testing the ability of the non-cleaved RANKL to stimulate osteoclast activation via direct cell:cell contact and generating knock in animals ( Figure 6 ).
Conclusions from Aim 2
Using a candidate approach we have found that MMPs that are highly expressed in the tumor-bone microenvironment (MMP-2, -3, -7) can process the factors that drive the vicious cycle. MMPs have primarily been considered as playing important roles in matrix degradation and while this may be true, clearly they are also playing key roles in regulating the availability and bioactivity of key factors such as PTHrP, RANKL and TGFβ. These discoveries have several innovations and highlight potential areas for therapeutic targeting.
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Our results have shown that individual MMPs can have differential effects in the tumor-bone microenvironment. Previously, MMP inhibitors failed in the clinical setting, primarily due to a lack of understanding as to how MMPs contribute to tumor progression. In animals models of osteolysis, broad spectrum MMP inhibitors have been successful in preventing tumor induced osteolysis and growth (26) (27) (28) . Therefore, in order to apply MMP inhibitors in the clinical setting, our results suggest that the selective targeting of MMP-2, MMP-7 and MMP-9 while sparing the activity of other metalloproteinase family members such as MMP-13 would be of benefit for the treatment of prostate to bone metastases. Finally, as a new investigator award mechanism, this grant from the DOD has been essential in allowing me to become an independent and established investigator. Based on my results acquired from this application, I have been able to generate an National Cancer Institute RO1
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